Quantcast

Latest Brain tumor Stories

2014-03-05 08:29:16

Lung, Prostate, and Brain Cancer Patients Receive Edge Radiosurgery at Champalimaud Center for the Unknown LISBON, Portugal, March 5, 2014 /PRNewswire/ -- Doctors at the Champalimaud Center for the Unknown here have performed the world's first cancer treatments using the new advanced Edge(TM) radiosurgery system from Varian Medical Systems (NYSE: VAR). This fast, precise and non-invasive alternative to conventional surgery was used to treat several patients with lung, prostate and...

2014-03-04 08:31:55

VANCOUVER, British Columbia and MENLO PARK, Calif., March 4, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") a pharmaceutical company developing its VAL-083 chemotherapy as a potential new therapy for glioblastoma multiforme, today announced that Jeffrey A. Bacha, President and CEO of DelMar Pharmaceuticals, Inc., will present at the upcoming 26(th) Annual ROTH Capital Conference. Mr. Bacha will make a corporate presentation to...

2014-02-27 23:32:09

New treatment center is first of its kind in the nation. St. Louis, MO (PRWEB) February 27, 2014 This month, brain tumor patient Charlie North became the first patient at St. Louis Children’s Hospital to undergo proton beam therapy, a type of radiation that holds great promise for pediatric patients. In late November of last year, Julia and Jake North of Paris, Ill., had their lives turned upside down when they received news that Charlie, the oldest of their 6-year-old triplets, had a...

2014-02-26 23:02:51

Jumpstarting Brain Tumor Drug Development Coalition hosts seminal workshop with brain tumor patient advocates, leading neuro-oncologists, biopharmaceutical industry representatives, FDA, and NCI to advance strategies for establishing better pathways for therapy evaluation. Bethesda, MD (PRWEB) February 26, 2014 Leaders from key cross-sections of the neuro-oncology community came together at a recent Brain Tumor Clinical Trial Endpoints Workshop to confront a critical challenge in...

New Imaging System Lights Up Tumors Using Scorpion Venom Protein And Laser
2014-02-26 10:42:27

Cedars-Sinai Medical Center Cedars-Sinai animal study may lead to human trial of experimental, compact intraoperative device to aid removal of malignant brain tumors Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery have developed a unique, compact, relatively inexpensive imaging device to "light up" malignant brain tumors and other cancers. The experimental system consists of a special camera designed and developed at Cedars-Sinai...

2014-02-26 08:28:38

Interim clinical data to be presented at American Association of Cancer Research (AACR) Annual Meeting on April 9, 2014 VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 26, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") provided an update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma (GBM). DelMar has completed enrollment of VAL-083 dose Cohort 5 and advanced to Cohort 6. DelMar...

2014-02-25 08:30:35

LOS ANGELES, Feb. 25, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the European Medicines Agency (EMA) has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during...

2014-02-20 12:15:21

St. Jude Children's Research Hospital--Washington University Pediatric Cancer Genome Project identifies the most common genetic alteration yet in the brain tumor ependymoma; results offer clues for fighting other cancers The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project has identified the most common genetic alteration ever reported in the brain tumor ependymoma and evidence that the alteration drives tumor development. The research appears...

2014-02-19 16:23:43

St. Jude Children's Research Hospital -Washington University Pediatric Cancer Genome Project identifies the most common genetic alteration yet in the brain tumor ependymoma; results offer clues for fighting other cancers MEMPHIS, Tenn., Feb. 19, 2014 /PRNewswire-USNewswire/ -- The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project has identified the most common genetic alteration ever reported in the brain tumor ependymoma and evidence that...

2014-02-18 08:32:26

The NovoTAL System Enables Certified Physicians to Plan and Individualize NovoTTF(TM) Therapy for Recurrent Glioblastoma Patients NEW YORK, Feb. 18, 2014 /PRNewswire/ -- Novocure announced today that Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center has licensed the NovoTAL (Transducer Array Layout) System. The NovoTAL System allows certified physicians to use a recurrent GBM patient's MRI data to optimize the distribution and intensity of NovoTTF Therapy....


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.